Compounds > dronabinol
Page last updated: 2024-08-21

dronabinol and Parkinsonian Disorders

dronabinol has been researched along with Parkinsonian Disorders in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Burger, F; Sidoroff, V; Szejko, N; Wenning, GK1
Dowd, E; Finn, DP; Gorman, AM; Walsh, S1
Bok, E; Chung, YC; Huh, SH; Jin, BK; Kim, SR; Kim, YS; Maeng, S; Park, JY; Park, SH; Yoon, SH1
Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B1
Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M1
Jongsma, MJ; Olivier, B; Philippens, IH; van Vliet, SA; Vanwersch, RA1

Other Studies

6 other study(ies) available for dronabinol and Parkinsonian Disorders

ArticleYear
Case Report: Secondary bilateral parkinsonism and dystonia treated with dronabinol.
    F1000Research, 2020, Volume: 9

    Topics: Adult; Basal Ganglia; Dronabinol; Dystonia; Dystonic Disorders; Humans; Parkinsonian Disorders

2020
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
    Brain research, 2010, Dec-02, Volume: 1363

    Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant

2010
Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
    Journal of immunology (Baltimore, Md. : 1950), 2011, Dec-15, Volume: 187, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoxazines; Cells, Cultured; Coculture Techniques; Corpus Striatum; Dopamine Agents; Dronabinol; Growth Inhibitors; Male; Mice; Mice, Inbred C57BL; Microglia; Morpholines; Naphthalenes; Neurons; Neurotoxins; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Substantia Nigra

2011
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Aug-15, Volume: 22, Issue:16

    Topics: Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Glutamic Acid; Glycerides; Hydrolysis; In Vitro Techniques; Membrane Potentials; Neurons; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Synaptic Transmission

2002
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug

2002
Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2008, Volume: 18, Issue:5

    Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Callithrix; Disease Models, Animal; Dronabinol; Female; Male; Modafinil; Parkinsonian Disorders

2008